ET-901 is under clinical development by EdiGene and currently in Phase II for Nodal Marginal Zone B-Cell Lymphoma. According to GlobalData, Phase II drugs for Nodal Marginal Zone B-Cell Lymphoma have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ET-901’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ET-901 overview

ET-901 is under development for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma, diffuse large B-cell lymphoma, systemic lupus erythematosus, primary mediastinal (thymic) large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma and marginal zone lymphoma (MZL), including nodal or splenic marginal zone B-cell lymphoma and mucosa-associated lymphoid tissue (MALT) lymphoma. It is administered through intravenous route and comprises of allogeneic T-cells genetically engineered to express chimeric antigen receptors (CAR) targeting CD19 expressing cells.

EdiGene overview

EdiGene is a China-based biotechnology company. The company develops genome editing technologies for a range of diseases and provides creative solutions to advance drug discovery.

For a complete picture of ET-901’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.